MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2025.1653456

Медицинская библиотека · Frontiers in immunology · 2025

Continuation of atezolizumab plus bevacizumab beyond initial progressive disease: clinical benefits in patients with unresectable hepatocellular carcinoma - a multicenter cohort study.

Tabuchi Takaya, Taniki Nobuhito, Ojiro Keisuke, Kasuga Ryosuke, Nakadai Yukie, Chu Po-Sung, Usui Shingo, Shiba Shunsuke, Tahara Toshiyuki, Komatsu Hirokazu, Fujita Yuriko, Kaneko Fumihiko, Hoshi Hitomi, Yamaguchi Akihiro, Fukuhara Seiichiro, Okamura Yukishige, Kanamori Hideaki, Ebinuma Hirotoshi, Tamura Masashi, Tsukada Jitsuro, Hasegawa Yasushi, Abe Yuta, Kitago Minoru, Jinzaki Masahiro, Kitagawa Yuko, Kanai Takanori, Nakamoto Nobuhiro

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод в очереди

Аннотация

BACKGROUND

The clinical significance of treatment beyond progression (TBP) with immune checkpoint inhibitor-based therapy in hepatocellular carcinoma (HCC) remains unclear. As atezolizumab plus bevacizumab has become a first-line therapy for advanced HCC, understanding the real-world outcomes of TBP is increasingly relevant.

METHODS

We conducted a multicenter retrospective observational study involving 122 patients with unresectable HCC treated with atezolizumab plus bevacizumab across nine liver centers in Japan. Among patients who experienced radiologic progressive disease (PD), clinical outcomes were compared between those who continued treatment beyond progression (TBP group) and those who discontinued therapy. Overall survival (OS), tumor response, and subgroup analyses based on major vessel involvement (MVI) were evaluated.

RESULTS

Among patients with PD, the median OS was not reached in the TBP group, compared to 13.6 months in the non-TBP group (HR 2.04; 95% CI 1.02-4.07; p=0.0435). When stratified by MVI status, patients without MVI who received TBP had significantly longer OS (median not reached) than those who received palliative care (median 6.2 months; HR 11.2; 95% CI 3.89-32.5; p<0.001). Among patients with MVI, TBP did not confer an OS benefit over palliative care (median OS: 10.4 months vs. 7.4 months; HR 2.24; p=0.260), whereas switching to subsequent chemotherapy showed improved OS (median 23.1 months vs. 7.4 months; HR 7.33; 95% CI 1.44-37.3; p=0.0164). Multivariate analysis identified MVI as an independent negative prognostic factor (HR 5.17; 95% CI 1.34-20.0; p=0.0172), even after adjusting for AFP ratio at progression.

CONCLUSIONS

This multicenter study suggests that continuation of atezolizumab plus bevacizumab beyond radiologic progression may improve survival outcomes in selected patients with unresectable HCC, particularly those without major vessel involvement. These findings support the integration of TBP into personalized treatment strategies in advanced HCC.

Для цитирования: Tabuchi Takaya, Taniki Nobuhito, Ojiro Keisuke, Kasuga Ryosuke, Nakadai Yukie, Chu Po-Sung, Usui Shingo, Shiba Shunsuke, Tahara Toshiyuki, Komatsu Hirokazu, Fujita Yuriko, Kaneko Fumihiko, Hoshi Hitomi, Yamaguchi Akihiro, Fukuhara Seiichiro, Okamura Yukishige, Kanamori Hideaki, Ebinuma Hirotoshi, Tamura Masashi, Tsukada Jitsuro, Hasegawa Yasushi, Abe Yuta, Kitago Minoru, Jinzaki Masahiro, Kitagawa Yuko, Kanai Takanori, Nakamoto Nobuhiro. Continuation of atezolizumab plus bevacizumab beyond initial progressive disease: clinical benefits in patients with unresectable hepatocellular carcinoma - a multicenter cohort study.. Frontiers in immunology. 2025. DOI: 10.3389/fimmu.2025.1653456.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.